Dr. Paige earned a Ph.D. in Immunology at the Sloan-Kettering Division of Cornell University Graduate School of Medical Sciences in 1979. He became a Member of the Basel Institute for Immunology in Switzerland where he worked from 1980-1987 before joining the Ontario Cancer Institute as a Senior Scientist in 1987. In 1990, Dr. Paige became the founding Director of the Arthritis and Autoimmunity Research Centre as well as Director of Research at The Wellesley Hospital. In 1998, he returned to the Ontario Cancer Institute to assume the role of Vice President, Research and, subsequently assumed his current position of Vice President, Research at the University Health Network, which comprises four hospitals: Toronto Rehab, Toronto General Hospital, Toronto Western Hospital and Princess Margaret Cancer Centre.
Dr. Paige is a Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto. He is an active educator in the undergraduate, graduate and postgraduate programs of the University’s School of Medicine. He is an internationally recognized leader in the area of lymphocyte development and antibody formation, with an active research program in training the immune system to recognize cancer cells.
He has served on the Research Advisory Boards of the National Cancer Institute and the Arthritis Society of Canada. He is the past Chairman of the Board of the Biotechnology Commercialization Centre which helped establish a Toronto Biotechnology Incubator and past Chairman of BioDiscovery Toronto, a consortium of 12 Toronto-based hospitals and universities engaged in the commercialization of research discoveries. He also serves on the Boards of the Terry Fox Research Institute, The Princess Margaret Cancer Foundation, Toronto General & Western Hospital Foundation, Arthritis Research Foundation, Council of Ontario Research Directors, and the Ontario Health Research Alliance. Dr. Paige is also a co-founder and Chairman of the Board of GEMMA Biotechnology. Its purpose is to discover and commercially develop biological response modifiers which influence the course of human disease. He was the Founder and co-Director of the Shanghai-Toronto Institute for Health Science (STI), a partnership between the Shanghai Institute of Health Sciences, Shanghai Institute of Organic Chemistry and the University Health Network. UHN currently maintains laboratories in the Zhangjiang High Technology Park in Pudong.
Industry Expertise (5)
Areas of Expertise (6)
Cornell University, Graduate School of Medical Sciences: Ph.D., Immunology 1979
- University of Toronto : Professor, Department of Medical Biophysics and Immunology
- Terry Fox Research Institute : Board Member
- The Princess Margaret Cancer Foundation : Board Member
- Council of Ontario Research Directors : Board Member
- Ontario Health Research Alliance : Board Member
- GEMMA Biotechnology : Co-Founder and Chairman
Bone resorption and remodeling is an intricately controlled, physiological process
that requires the function of osteoclasts. The processes governing both the differentiation
and activation of osteoclasts involve signals induced by osteoprotegerin ligand (OPGL), a ...
Only mature B lymphocytes can enter the lymphoid follicles of spleen and lymph
nodes and thus efficiently participate in the immune response. Mature, long-lived B
lymphocytes derive from short-lived precursors generated in the bone marrow. We show ...
Interferon regulatory factor 1 (IRF-1), a transcriptional activator, and its
antagonistic repressor, IRF-2, were originally identified as regulators of the type I interferon
(IFN) system. We have generated mice deficient in either IRF-1 or IRF-2 by gene targeting ...
CD44 is expressed in various isoforms on numerous cell types and tissues during
embryogenesis and in the mature organism. CD44 may also be involved in tumor growth. To
study the multiple roles of CD44, we abolished expression of all known isoforms of CD44 ...
The transmembrane tyrosine phosphatase CD45 is expressed in multiple isoforms
on all nucleated hematopoietic cells, resulting from alternative splicing of variable exons. We
generated mice with a mutation in the variable CD45 exon 6, using homologous ...